Navigation Links
Further 100 Million Euros Allocated to Netherlands-Based R&D Targeting the Early Diagnosis and Treatment of Disease

EINDHOVEN, The Netherlands, March 10 /PRNewswire/ -- The Center for Translational Molecular Medicine (CTMM) - the Dutch public-private partnership committed to the research and development of new techniques for the diagnosis and treatment of major diseases - today announced that eight new research projects will receive funding from the CTMM. It means that almost 250 million Euros have now been allocated to Netherlands-based translational projects that could radically improve patient outcomes for diseases such as Alzheimer's, rheumatoid arthritis, sepsis, cardiovascular disorders and the most important forms of cancer.

The eight new projects, each of which comprises a consortium of clinical and industrial partners, involve 13 leading university medical centers and research institutes, 29 expert SMEs (Small and Medium-sized Enterprises) and 15 major industrial players. 50% of the funding for these new projects is being contributed by the Dutch Government. The other 50% will come from industry and academia.

In line with the CTMM's original business plan, the newly approved projects include projects that target cancer, cardiovascular, neurodegenerative and infectious diseases. They also include projects to develop innovative new technology platforms, such as new medical imaging techniques, that can be applied across a broad spectrum of these diseases. The need for broad-based technology platforms in translational molecular medicine is underlined by the fact that all three technical universities that make up the Netherlands' 3TU.Federation (Delft, Eindhoven and Twente) are now involved in the CTMM.

Speaking on behalf of the 3TU.Federation, Amandus Lundqvist, President of the Technical University of Eindhoven (TU/e) said, "By applying our combined expertise in areas such as bio-nano applications, ICT systems and applied technology to CTMM projects, we believe we can help to boost the competitive position and innovative power of the Dutch knowledge-based society as well as improve the well-being of its people."

Following advice from its International Scientific Advisory Committee, the CTMM will continue to provide selective investments in centralised infrastructures for CTMM projects to address the rapidly increasing demand for advanced genomics, proteomics, metabolomics and bioinformatics. In close collaboration with the other major Dutch translational programs in the life sciences (TI Pharma, BMM, NGI and the "String of Pearls Initiative"), these efforts will substantially strengthen the translational research climate in the Netherlands.

For general information please visit our website at For information on the projects, click the 'Projects' tab on our website.

About CTMM

The CTMM (Center for Translational Molecular Medicine) is a Netherlands-based public-private partnership dedicated to the development of technologies in molecular medicine that enable early diagnosis and personalized treatment for oncology, cardiovascular, neurodegenerative and infectious/auto-immune disease - the four main areas of disease causing mortality and diminished quality of life in the western world. CTMM operates by inviting, assessing and funding multidisciplinary projects that involve active participation by Netherlands-based academia and industry. All CTMM projects are judged by an independent International Advisory Board and approved by a Supervisory Board based on their significant potential to translate research knowledge into clinical practice. The CTMM is funded by the Dutch government (50%), academia (25%) and industry (25%). For more information, visit

    The other major Dutch translational programs in the life sciences:
    TI Pharma (Top Institute Pharma):
    BMM (BioMedical Materials Program):
    NGI (Netherlands Genomics Initiative):
    String of Pearls Initiative (Parelsnoer):

Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
3. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
4. Adds Mobile Phone Capability Further Speeding Access to Experienced Monitors
5. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
6. Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder
7. Agencourt Genomic Services is Key Collaborator in New Research That Further Defines Landscape of Breast and Colon Cancers
8. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
9. SAFC Hitech(TM) Plans Further Expansion Into Asia
10. CleveMed Receives $1.5 Million in NIH Funding to Further Develop a Portable System for Monitoring Parkinsons Disease Motor Symptoms
11. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
Post Your Comments:
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. Hays ... DNA as a Field Application Specialist. , “I am thrilled that Dr. Young ... DNA. “In further expanding our capacity as a scientific integrator, Hays brings a wealth ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free validated ... will showcase its product’s latest features from June 26 to June 30, 2016 ... on Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug ...
Breaking Biology Technology:
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: ) , ... services, but it also plays a fundamental part in enabling ...
Breaking Biology News(10 mins):